Why do cancer drugs get such an easy ride?
Authors:
Abstract
Rushed approvals result in a poor deal for both patients and cancer research Unlike most other diseases, cancer instils a special fear and “is treated as an evil, invincible predator, not just a disease.”1 The ability of drug companies to charge very high prices, even when most approved cancer drugs provide little gain for patients, drives much of the research, as desperate patients lead some governments and private insurers to pay whatever companies charge. Officials within the US Food and Drug Administration are enthusiastic about new cancer drugs. Richard Pazdur, who oversees oncology activities for the FDA says that new cancer drugs are so effective that “We don’t have a lot of questions on [these] drugs because they’re slam dunks. It’s not if we’re going to approve them. It’s how fast we’re going to approve them.”2 The methodological weaknesses in oncology trials do not support such enthusiasm. Researchers compared 8942 oncology clinical trials conducted between 2007 and 2010 with trials for other diseases.3 Trials for cancer drugs were 2.8 times more likely not to be randomised, 2.6 times more likely not to use a comparator (single arm), and 1.8 …Keywords
This publication has 14 references indexed in Scilit:
- Progression-Free Survival: Helpful Biomarker or Clinically Meaningless End Point?Journal of Clinical Oncology, 2015
- Unintended Consequences of Expensive Cancer Therapeutics—The Pursuit of Marginal Indications and a Me-Too Mentality That Stifles Innovation and CreativityJAMA Otolaryngology–Head & Neck Surgery, 2014
- American Society of Clinical Oncology Perspective: Raising the Bar for Clinical Trials by Defining Clinically Meaningful OutcomesJournal of Clinical Oncology, 2014
- New FDA Breakthrough-Drug Category — Implications for PatientsNew England Journal of Medicine, 2014
- Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trialsNeuro-Oncology, 2013
- Market spiral pricing of cancer drugsCancer, 2013
- Characteristics of Oncology Clinical TrialsJAMA Internal Medicine, 2013
- Additional safety risk to exceptionally approved drugs in Europe?British Journal of Clinical Pharmacology, 2011
- Ten years of marketing approvals of anticancer drugs in Europe: regulatory policy and guidance documents need to find a balance between different pressuresBritish Journal of Cancer, 2005
- End Points and United States Food and Drug Administration Approval of Oncology DrugsJournal of Clinical Oncology, 2003